Show simple item record

dc.contributor.authorCollinson, Fiona J
dc.contributor.authorJayson, Gordon C
dc.date.accessioned2009-07-16T09:11:06Z
dc.date.available2009-07-16T09:11:06Z
dc.date.issued2009-02
dc.identifier.citationNew therapeutic agents in ovarian cancer. 2009, 21 (1):44-53 Curr. Opin. Obstet. Gynecol.en
dc.identifier.issn1473-656X
dc.identifier.pmid19125003
dc.identifier.doi10.1097/GCO.0b013e32831ffe71
dc.identifier.urihttp://hdl.handle.net/10541/74033
dc.description.abstractPURPOSE OF REVIEW: Despite advances in management over recent years, epithelial ovarian cancer remains the most lethal gynaecological malignancy. Methods of early detection, as well as improved therapeutic options, are urgently needed. RECENT FINDINGS: Currently, a number of targeted therapies, including vascular endothelial growth factor inhibitors, poly-ADP-ribose polymerase inhibitors and folate receptor inhibitors look promising in this arena and this article will review a number of these drugs and the evidence pertaining to their use. SUMMARY: Much further research is required to define if, when and how best to integrate these novel therapies, and also to define associated biomarkers that predict toxicity and select patients most likely to derive benefit. Individualized therapy is not an impossible dream, but there is still a long way to go.
dc.language.isoenen
dc.subjectOvarian Canceren
dc.subjectTargeted Therapiesen
dc.subject.meshAngiogenesis Inhibitors
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntineoplastic Agents
dc.subject.meshCarboplatin
dc.subject.meshDrug Administration Routes
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshNeovascularization, Pathologic
dc.subject.meshOvarian Neoplasms
dc.subject.meshPaclitaxel
dc.subject.meshPoly Adenosine Diphosphate Ribose
dc.subject.meshProtein Kinase Inhibitors
dc.subject.meshProteins
dc.subject.meshRandomized Controlled Trials as Topic
dc.subject.meshReceptor, Epidermal Growth Factor
dc.subject.meshVascular Endothelial Growth Factor A
dc.titleNew therapeutic agents in ovarian cancer.en
dc.typeArticleen
dc.typeBooken
dc.contributor.departmentUniversity of Leeds, St James' University Hospital, Leeds, UK. fjcollinson@doctors.org.uken
dc.identifier.journalCurrent Opinion in Obstetrics & Gynecologyen
html.description.abstractPURPOSE OF REVIEW: Despite advances in management over recent years, epithelial ovarian cancer remains the most lethal gynaecological malignancy. Methods of early detection, as well as improved therapeutic options, are urgently needed. RECENT FINDINGS: Currently, a number of targeted therapies, including vascular endothelial growth factor inhibitors, poly-ADP-ribose polymerase inhibitors and folate receptor inhibitors look promising in this arena and this article will review a number of these drugs and the evidence pertaining to their use. SUMMARY: Much further research is required to define if, when and how best to integrate these novel therapies, and also to define associated biomarkers that predict toxicity and select patients most likely to derive benefit. Individualized therapy is not an impossible dream, but there is still a long way to go.


This item appears in the following Collection(s)

Show simple item record